Related Experiment Video
Updated: Jul 21, 2026

13:19
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013
16.7K
Exploring wait time variations in a prostate cancer patient pathway-A qualitative study.
Anne Grete Valbekmo1, Lise Mo2, Gudveig Gjøsund3
1Helse Nord-Trøndelag Hospital Trust, Levanger, Norway.
The International Journal of Health Planning and Management
|March 29, 2022
Summary
Prostate cancer patients face longer wait times at local hospitals due to system factors. Differences in hospital capacity and patient transfer processes significantly impact cancer patient pathways (CPPs).
Area of Science:
- Health Services Research
- Oncology
- Healthcare Management
Background:
- Norwegian health authorities aim for equitable healthcare access via cancer patient pathways (CPPs).
- Prostate cancer statistics reveal disparities in wait times between local and university hospitals.
Purpose of the Study:
- To identify health system-related factors influencing variations in diagnostic wait times for prostate cancer patients.
- To compare these factors between local and university hospital settings.
Main Methods:
- Qualitative study involving 18 healthcare workers through semi-structured interviews.
- Systematic text condensation used for thematic analysis of interview transcripts.
Main Results:
- Four key factors identified: capacity/competence, logistics/efficiency, need for specialized investigations, and extra consultations.
- Local hospitals frequently reported capacity limitations compared to university hospitals.
- Centralized surgery led to patient transfers, adding steps and time to the cancer patient pathway (CPP).
Conclusions:
- Variations in wait times are influenced by internal hospital organization of cancer patient pathways (CPPs) and inter-hospital patient transfer processes.
- Hospital capacity differences are a significant driver of wait time disparities.
- Additional steps in patient transfers contribute to extended time within the cancer patient pathway (CPP).

